Latest Insider Transactions at Inspire Medical Systems, Inc. (INSP)
This section provides a real-time view of insider transactions for Inspire Medical Systems, Inc. (INSP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Inspire Medical Systems, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Inspire Medical Systems, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2024
|
Marilyn C Nelson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,243
+5.07%
|
$366,459
$113.64 P/Share
|
|
Mar 25
2024
|
Jerry C Griffin Director |
SELL
Open market or private sale
|
Direct |
554
-2.49%
|
$109,138
$197.81 P/Share
|
|
Mar 25
2024
|
Jerry C Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+8.2%
|
$16,000
$16.0 P/Share
|
|
Mar 22
2024
|
John Rondoni Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
4,387
-10.05%
|
$851,078
$194.46 P/Share
|
|
Mar 18
2024
|
Jerry C Griffin Director |
SELL
Open market or private sale
|
Direct |
554
-2.59%
|
$106,922
$193.53 P/Share
|
|
Mar 18
2024
|
Jerry C Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+8.52%
|
$16,000
$16.0 P/Share
|
|
Mar 11
2024
|
Jerry C Griffin Director |
SELL
Open market or private sale
|
Direct |
554
-2.7%
|
$109,692
$198.05 P/Share
|
|
Mar 11
2024
|
Jerry C Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+8.85%
|
$16,000
$16.0 P/Share
|
|
Mar 01
2024
|
Marilyn C Nelson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,555
+8.41%
|
$0
$0.94 P/Share
|
|
Mar 01
2024
|
Jerry C Griffin Director |
SELL
Open market or private sale
|
Direct |
554
-3.12%
|
$99,166
$179.44 P/Share
|
|
Mar 01
2024
|
Jerry C Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+9.21%
|
$16,000
$16.0 P/Share
|
|
Feb 29
2024
|
John Rondoni Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
8,605
-9.74%
|
$1,540,295
$179.61 P/Share
|
|
Feb 27
2024
|
Randy Ban Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,060
-50.25%
|
$556,920
$182.01 P/Share
|
|
Feb 27
2024
|
Randy Ban Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,060
+33.45%
|
$128,520
$42.15 P/Share
|
|
Feb 23
2024
|
Randy Ban Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,230
-80.15%
|
$2,262,550
$185.37 P/Share
|
|
Feb 23
2024
|
Randy Ban Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,230
+24.94%
|
$256,830
$21.55 P/Share
|
|
Feb 15
2024
|
John Rondoni Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+24.8%
|
$16,000
$2.07 P/Share
|
|
Feb 09
2024
|
Randy Ban Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,694
+47.07%
|
-
|
|
Feb 09
2024
|
Bryan K Phillips Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,694
+37.08%
|
-
|
|
Feb 09
2024
|
Philip Ebeling Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,694
+47.09%
|
-
|
|
Feb 09
2024
|
John Rondoni Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,694
+14.21%
|
-
|
|
Feb 09
2024
|
Richard Buchholz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,694
+5.86%
|
-
|
|
Feb 09
2024
|
Charisse Y Sparks Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,694
+42.19%
|
-
|
|
Feb 09
2024
|
Timothy P. Herbert CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
8,467
+46.63%
|
-
|
|
Feb 09
2024
|
Carlton Weatherby Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,694
+50.0%
|
-
|
|
Feb 09
2024
|
Marilyn C Nelson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+13.67%
|
$0
$0.94 P/Share
|
|
Jan 30
2024
|
Steven Jandrich VP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
16,225
+41.26%
|
$0
$0.94 P/Share
|
|
Jan 29
2024
|
Bryan K Phillips Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
205
-9.85%
|
$44,280
$216.61 P/Share
|
|
Jan 16
2024
|
Charisse Y Sparks Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5
+0.28%
|
$1,190
$238.19 P/Share
|
|
Jan 16
2024
|
Shelley G. Broader Director |
BUY
Grant, award, or other acquisition
|
Direct |
97
+2.04%
|
$21,340
$220.83 P/Share
|
|
Jan 16
2024
|
Gary Lee Ellis Director |
BUY
Grant, award, or other acquisition
|
Direct |
97
+0.98%
|
$21,340
$220.83 P/Share
|
|
Jan 16
2024
|
Marilyn C Nelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
167
+0.26%
|
$36,740
$220.83 P/Share
|
|
Jan 16
2024
|
Georgia Melenikiotou Director |
BUY
Grant, award, or other acquisition
|
Direct |
90
+2.16%
|
$19,800
$220.83 P/Share
|
|
Jan 16
2024
|
Casey M Tansey Director |
BUY
Grant, award, or other acquisition
|
Direct |
87
+0.15%
|
$19,140
$220.83 P/Share
|
|
Dec 21
2023
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,384
+50.0%
|
-
|
|
Oct 17
2023
|
Marilyn C Nelson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+4.63%
|
$0
$0.94 P/Share
|
|
Oct 13
2023
|
Shelley G. Broader Director |
BUY
Grant, award, or other acquisition
|
Direct |
99
+6.5%
|
$14,850
$150.47 P/Share
|
|
Oct 13
2023
|
Charisse Y Sparks Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25
+2.72%
|
$3,750
$150.47 P/Share
|
|
Oct 13
2023
|
Marilyn C Nelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
141
+0.73%
|
$21,150
$150.47 P/Share
|
|
Oct 13
2023
|
Gary Lee Ellis Director |
BUY
Grant, award, or other acquisition
|
Direct |
99
+3.06%
|
$14,850
$150.47 P/Share
|
|
Oct 13
2023
|
Georgia Melenikiotou Director |
BUY
Grant, award, or other acquisition
|
Direct |
91
+6.84%
|
$13,650
$150.47 P/Share
|
|
Oct 13
2023
|
Casey M Tansey Director |
BUY
Grant, award, or other acquisition
|
Direct |
87
+0.42%
|
$13,050
$150.47 P/Share
|
|
Oct 12
2023
|
Charisse Y Sparks Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
100
+9.11%
|
$15,300
$153.5 P/Share
|
|
Oct 12
2023
|
Timothy P. Herbert CEO and President |
SELL
Payment of exercise price or tax liability
|
Indirect |
98,720
-14.42%
|
$14,511,840
$147.89 P/Share
|
|
Oct 12
2023
|
Timothy P. Herbert CEO and President |
BUY
Exercise of conversion of derivative security
|
Indirect |
208,036
+24.9%
|
$1,040,180
$5.94 P/Share
|
|
Sep 21
2023
|
Marilyn C Nelson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+9.54%
|
$0
$0.94 P/Share
|
|
Sep 14
2023
|
Marilyn C Nelson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+10.55%
|
$0
$0.94 P/Share
|
|
Sep 08
2023
|
Timothy P. Herbert CEO and President |
SELL
Open market or private sale
|
Indirect |
47,992
-31.03%
|
-
|
|
Sep 08
2023
|
Timothy P. Herbert CEO and President |
SELL
Bona fide gift
|
Indirect |
47,992
-31.03%
|
-
|
|
Aug 28
2023
|
Steven Jandrich VP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+26.68%
|
$0
$0.94 P/Share
|